TIINA ALAHUHTA-KASKO IS APPOINTED AS PRESIDENT OF MARIMEKKO

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TIINA ALAHUHTA-KASKO IS APPOINTED AS PRESIDENT OF MARIMEKKO – MIKA IHAMUOTILA CONTINUES AS CEO AND IS AVAILABLE FOR ELECTION AS CHAIRMAN OF THE BOARD

Marimekko Corporation, Stock Exchange Release, 12 February 2015 at 8.30

TIINA ALAHUHTA-KASKO IS APPOINTED AS PRESIDENT OF MARIMEKKO – MIKA IHAMUOTILA CONTINUES AS CEO AND IS AVAILABLE FOR ELECTION AS CHAIRMAN OF THE BOARD

Mr Pekka Lundmark, the Chairman of the Board of Directors of Marimekko Corporation since 2008, has informed the company that he will no longer be available for re-election in Marimekko’s Board at the Annual General Meeting of Shareholders to be held on 9 April 2015. In connection with this, Mr Mika Ihamuotila, the current President and CEO and Vice Chairman of the Board, has announced that he will be available for election as the Chairman of the Board and that he will step down from his position as the President of Marimekko.

On 11 February 2015, the Board of Directors of Marimekko resolved to appoint Ms Tiina Alahuhta-Kasko (b. 1981) as the new President of Marimekko. She has acted as the Chief Operating Officer (COO) of Marimekko since 2014 and has also since 2011 held the position of Chief Marketing Officer (CMO) and been a member of Marimekko’s Management Group.
Tiina Alahuhta-Kasko, M. Sc. (Econ.), CEMS MIM, joined Marimekko in 2005. Following her new appointment, the tasks of COO will be included in the duties of the President and hence a new COO will not be appointed. The company has commenced a process to recruit a Marketing Director.

The Board of Directors of Marimekko simultaneously decided on a full-time executive service agreement with Mika Ihamuotila regarding his role as CEO. His duties will include, e.g., responsibility for the development of Marimekko’s strategy and its implementation together with the President and the Management Group, as well as an active senior role in managing the company’s financial affairs and stakeholder relations. Furthermore, Mika Ihamuotila will have a senior role in developing leadership within the Marimekko Group. Ihamuotila’s executive agreement or his duties thereunder are not dependent on his position as a member or Chairman of Marimekko’s Board of Directors.

Both appointments will enter into force on 9 April 2015 as of the close of the Annual General Meeting of Shareholders. In the event that Mika Ihamuotila is also elected the Chairman of the Board of Directors, his title and position will be Chairman and CEO.


Tiina Alahuhta-Kasko, as President, will act as the chairman of Marimekko’s Management Group as of 9 April 2015. The responsibilities of the members of the Management Group will otherwise remain unchanged. To discuss significant strategic matters, the Management Group will convene under the chairmanship of the CEO at regular intervals .

As part of revising Marimekko’s governance structure, the Board of Directors has resolved that an Audit and Remuneration Committee will be established. All members of the committee will be independent of Marimekko and its major shareholders. The first Audit and Remuneration Committee will be elected from among its members by the new Board of Directors elected by the Annual General Meeting of Shareholders to be held on 9 April 2015. In addition to tasks typically assigned to audit and remuneration committees and supervision, the Audit and Remuneration Committee will handle and prepare matters relating to the terms and remuneration of Marimekko’s executive management.

”As her immediate superior, I have had the pleasure of following and supporting the development of Tiina Alahuhta-Kasko as a Marimekko executive during the past seven years. I am delighted that our new President comes from within the company. In my view, Tiina Alahuhta-Kasko is a truly exceptional person and leader: insightful, efficient, inspiring and fair-minded. I myself am committed to continuing my work at Marimekko as a shareholder and in my new capacity and, together with Tiina Alahuhta-Kasko, to making Marimekko into an even more attractive, international and profitable design company,” says Mika Ihamuotila.

"In my various roles over the last nearly ten years, I have had the chance to see the opportunities for Marimekko around the world, from Asia to Australia and North America. I would like to thank Mika Ihamuotila and Marimekko's Board of Directors for the confidence they have placed in me; I cannot think of a more inspiring challenge than taking Marimekko forward together with our amazing staff. Our joint objective is to offer our customers even more interesting products and experiences, and increase our profitability while gaining a stronger foothold in the global market," says Tiina Alahuhta-Kasko.

Further information
Please address requests for interviews to Annikka Itkonen, Communications Manager, tel.
+358 9 758 7220, annikka.itkonen@marimekko.com

Photos: http://mediabank.marimekko.fi/?cart=8949-bghmhidmcl&l=EN


MARIMEKKO CORPORATION
Board of Directors

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Key media


Marimekko is a Finnish design company renowned for its original prints and colours. The company’s product portfolio includes high-quality clothing, bags and accessories as well as home décor items ranging from textiles to tableware. When Marimekko was founded in 1951, its unparalleled printed fabrics gave it a strong and unique identity. Marimekko products are sold in about 40 countries. In 2014, brand sales of the products worldwide amounted to EUR 187 million and the company's net sales were EUR 94 million. More than 140 Marimekko stores serve customers around the globe. The key markets are Northern Europe, North America and the Asia-Pacific region. The Group employs about 500 people. The company’s share is quoted on NASDAQ OMX Helsinki Ltd. www.marimekko.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 29

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 17

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 16

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 22

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 23

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Context Therapeutics Gains Confidence with Strategic Developments

Updated Category News Views 60

Piper Sandler's Renewed Confidence in Context Therapeutics Piper Sandler has reiterated an Overweight rating for Context Therapeutics (NASDAQ: CNTX), maintaining a price target of $4.50 for the stock. This endorsement underscores their belief in the company’s potential within the biopharmaceutical sector. Positive Data from Competitors Enhances Expectations This renewed...

Continue Reading
Actinium's ATNM-400: A Promising Frontier in Prostate Cancer Therapy

Updated Category News Views 167

Introduction to ATNM-400's Innovative Approach Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced compelling preclinical data showcasing its innovative treatment, ATNM-400. This first-in-class antibody radioconjugate targets a unique, non-PSMA antigen, revolutionizing prostate cancer therapy. ATNM-400 offers noteworthy therapeutic activity independent of...

Continue Reading
Opportunity Knocks: Ligon's Major Auction Up for Bids

Updated Category News Views 17

Equipment Auction Offers Unique Buying Opportunity Catch this: Ligon Co.'s auction is like finding a needle in a haystack in a world of overpriced equipment. We're talking about a smorgasbord of heavy machinery up for online grabs, and it’s happening until June 17. Auction Highlights: Your Next Business Asset? From telehandlers to trailers, this ain't your everyday yard...

Continue Reading
Selector Enhances Service Delivery with AWS Marketplace Launch

Updated Category News Views 147

Selector Launches on AWS Marketplace for Better Accessibility Selector, a pioneer in AI-driven observability and network intelligence, is transforming how organizations manage their network operations. The company has launched its flagship platform on the Amazon Web Services (AWS) Marketplace, which makes it easier for customers to procure and deploy its powerful AI tools...

Continue Reading
Exploring the Surge in Decentralized Energy Storage Growth

Updated Category News Views 229

Decentralized Energy Storage Market Overview The Decentralized Energy Storage market is gaining remarkable traction, with significant insights indicating a shift towards sustainable energy solutions. Valued at approximately USD 10.88 billion, the market is anticipated to expand to a staggering USD 35.62 billion, exhibiting a compound annual growth rate (CAGR) of 15.98%...

Continue Reading